RxDoctor Payments Data

Christopher Hermann, MD

Internal Medicine · Doylestown, PANPI 1063469344

Payments from drug & device makers

$1,101in general payments, 2019–2025

Across 58 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$217
  • Novo Nordisk$175
  • Pfizer$173
  • Lilly USA, LLC$109
  • Acadia Pharmaceuticals Inc$94
  • Merck$70
  • plus $264 from 9 others

What the payments were for

  • Food & beverage$1,101100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,101 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$216,889
Medicare patients
400
Services billed
2,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin73$78,449
JanuviaSitagliptin Phosphate60$68,226
EliquisApixaban66$55,604
OzempicSemaglutide29$48,458
InvokanaCanagliflozin20$32,174
TrulicityDulaglutide21$31,228
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$26,471
JanumetSitagliptin Phos/Metformin Hcl16$25,455
FarxigaDapagliflozin Propanediol24$15,308
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$12,541
MyrbetriqMirabegron12$6,270
Atorvastatin Calcium332$4,706
Serevent DiskusSalmeterol Xinafoate11$4,624
Tiotropium Bromide11$4,564
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$4,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$70$93,68276 claims
Boehringer IngelheimJardiance$40$78,44973 claims
PfizerEliquis$173$55,60466 claims
Novo NordiskOzempic$175$48,45829 claims
Johnson & JohnsonInvokana$12$32,17420 claims
Lilly USA, LLCTrulicity$109$31,22821 claims
AstraZenecaFarxiga$217$15,30824 claims
GSKTrelegy Ellipta$17$12,54119 claims
AbbVieSynthroid$24$3,79653 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →